[EQ] 2010 Global report on surveillance and response: Multidrug and extensively drug-resistant TB (M/XDR-TB)

Multidrug and extensively drug-resistant TB (M/XDR-TB)
2010 Global report on surveillance and response

World Health Organization, 2010

…..Drug-resistant tuberculosis now at record levels….

Available online PDF [71p.]  at: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf

18 MARCH 2010 | GENEVA | WASHINGTON DC – “……In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says.

For example, 28% of all people newly diagnosed with TB in one region of north western Russia had the multidrug-resistant form of the disease (MDR-TB) in 2008. This is the highest level ever reported to WHO. Previously, the highest recorded level was 22% in Baku City, Azerbaijan, in 2007.

In the new WHO's Multidrug and Extensively Drug-Resistant Tuberculosis: 2010 Global Report on Surveillance and Response, it is estimated that 440 000 people had MDR-TB worldwide in 2008 and that a third of them died. In sheer numbers, Asia bears the brunt of the epidemic. Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India. In Africa, estimates show 69 000 cases emerged, the vast majority of which went undiagnosed…..”

Content:

Summary

Introduction

Part I: Surveillance of M/XDR-TB

1.1 Geographical coverage of anti-TB drug resistance data

1.2 Resistance to first-line anti-TB drugs, including MDR-TB

1.3 Risk factors for drug resistance: previous treatment, sex and HIV

1.4 Trends over time

1.5 Resistance to second-line anti-TB drugs, including XDR-TB

1.6 Estimated global burden of MDR-TB

Part II: Progress in the global response to M/XDR-TB  

2.1 Scaling up laboratory services for diagnosis of M/XDR-TB

2.2 Reporting of MDR-TB patients and their treatment outcomes

2.3 Addressing other health systems considerations for the response to M/XDR-TB

2.4 Financing the care of drug-resistant TB patients in the 27 high MDR-TB burden countries

References
Annexes

 *      *     *
This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate
information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic
health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics;
Information Technology - Virtual libraries; Research & Science issues.  [DD/ KMC Area]

“Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings
and interpretations included in the Materials are those of the authors and not necessarily of The Pan American
Health Organization PAHO/WHO or its country members”.
------------------------------------------------------------------------------------
PAHO/WHO Website
Equity List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html
Twitter http://twitter.com/eqpaho

 

    IMPORTANT: This transmission is for use by the intended recipient and it may contain privileged, proprietary or confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please notify us immediately by email to infosec@paho.org, and please dispose of and delete this transmission. Thank you.